GC012F (AZD0120)
A Phase 1 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Early-Line Treatment in Subjects With Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 18 patients (estimated)
- Sponsors
- AstraZeneca
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA), CD19, High Risk, Monotherapy, Open Label, Single Cohort
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 2146
- NCT Identifier
- NCT07073547
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.